Stu<strong>di</strong>o, anno(referenza)Sidney S,P<strong>et</strong>itti DB, SoffGA, Cun<strong>di</strong>ffDL, Tolan KK,QuesenberryCP, Jr. Venousthromboembolic<strong>di</strong>sease inusers of lowestrogencombinedestrogenprogestinor<strong>al</strong>contraceptivesContraception2004; 70(1):3-10.S<strong>et</strong>ting/DisegnoStu<strong>di</strong>o casocontrolloDonne tra 15e 44 annipartecipanti<strong>al</strong> KaiserPermanenteMe<strong>di</strong>c<strong>al</strong>CareProgram[KPMCP](NorthernandSouthernC<strong>al</strong>ifornia)condotto tra1998-2000popolazione(N)196 paz.v<strong>al</strong>utate su379 casi <strong>di</strong>TEV con80.8% <strong>di</strong>interviste edopoesclusione<strong>di</strong> 103.Usocorrente <strong>di</strong>EP : 44%Gruppo <strong>di</strong>controllo746controlliscelti arandom su1404potenzi<strong>al</strong>i(58%intervistatie dopoesclusione<strong>di</strong> 73sogg<strong>et</strong>ti),usocorrente <strong>di</strong>EP: 18%InterventiSottopostea prelievo <strong>di</strong>sangue e<strong>di</strong>ntervista conquestionariostrutturato suuso <strong>di</strong> EP abassa dose <strong>di</strong>estrogeni datidemografici,storiaperson<strong>al</strong>e,immobilizzazioneprolungata,stile <strong>di</strong> vita,uso <strong>di</strong>aspirina osupplementivitaminici.Outcomes erisultatiORBMI tra 25-30: 1.78(1.14-2.77)BMI >30:3.47 (2.35-5.10)Prolungataimmobilizzazionenelle 6s<strong>et</strong>timaneprecedenti:5.93 (4.18–8.41);m<strong>al</strong>attieme<strong>di</strong>che:5.27 (3.74–7.42)storiafamiliare:1.69 (1.06–2.70)ve<strong>di</strong> tavola1 e 4.CommentiNon dati su EPcon gestodene edesogestrel(nessun uso);possibile rec<strong>al</strong>lbias su uso <strong>di</strong> OC,<strong>di</strong>agnostic bias,peso ed <strong>al</strong>tezzariferiti d<strong>al</strong>lepazienti,eff<strong>et</strong>to <strong>di</strong> obesitànegli USA (m<strong>et</strong>à <strong>di</strong>sogg<strong>et</strong>ti con TEVin EP eranoobese)Stu<strong>di</strong>o, anno(referenza)Siritho S,Thrift AG,McNeil JJ,You RX,Davis SM,Donnan GA.Risk ofischemicstrokeamong usersof the or<strong>al</strong>contraceptivepill: TheMelbourneRisk FactorStudy(MERFS)Group.Stroke 2003;34(7):1575-1580.S<strong>et</strong>ting/DisegnoMelboureAustr<strong>al</strong>ia , in4 osped<strong>al</strong>iCasocontrolloTra 1984 e1996MERFS(TheMelbourneRisk FactorStudy)popolazione(N)234 donne tra 15–55 annicon ictusischemico dellaqu<strong>al</strong>i solo 35(15%)assumevanoOC <strong>al</strong> momentodell’ictus.Gruppo <strong>di</strong>controllo234 donne<strong>di</strong> <strong>et</strong>àcomparabile+/- 5 aaselezionatenella stessoquartiere <strong>di</strong>provenienzadei casidelle qu<strong>al</strong>isolo 28(12%)assumevanoEPInterventiQuestionariostrutturato sufattori <strong>di</strong>rischio CV estoriafamiliare perm<strong>al</strong>attie CVsomministratocirca 7 mesidopo strokenei casi e neicontrolli 2.5mesi dopointervista aicasiOutcomes erisultatiEff<strong>et</strong>tosignificativosolo <strong>di</strong> fattori<strong>di</strong> rischio Cvqu<strong>al</strong>i fumo,ipertensione,<strong>di</strong>ab<strong>et</strong>e,pregressoIma o TIA,non eff<strong>et</strong>to<strong>di</strong> EP,eff<strong>et</strong>tosignificativo<strong>di</strong> storiafamiliare <strong>di</strong>ictus edobesità.Noninterazion<strong>et</strong>ra EP eipertensioneo fumo.CommentiSolo EPconbassocontenuto<strong>di</strong>estrogeni,pochi casi<strong>di</strong> ictusischemicocon EP.Possibilerec<strong>al</strong>lbias16
Stu<strong>di</strong>o, anno(referenza)SchwaagS, NabaviDG, FreseA,HusstedtIW, EversS. Theassociationb<strong>et</strong>weenmigraineandjuvenilestroke: acasecontrolstudy.Headache2003;43(2):90-95.S<strong>et</strong>ting/DisegnoUniversity ofMunster,GermaniaCaso-controlloin 3 anni ( manon specificainterv<strong>al</strong>lo <strong>di</strong>tempo)popolazione(N)160 paz.
Change language